Literature DB >> 12788307

Prolactin enhances production of interferon-gamma, interleukin-12, and interleukin-10, but not of tumor necrosis factor-alpha, in a stimulus-specific manner.

Khalid Z Matalka1.   

Abstract

Prolactin, an anterior pituitary hormone, has been shown to have a role in immunomodulation. Some reports have shown the importance of prolactin in activating lymphocytes and macrophages, while in hyperprolactinemia patients, prolactin was found to decrease lymphocyte activation and natural killer function. In the present work, at physiological (15ng/ml) and stress-induced levels (30ng/ml) of prolactin, interferon-gamma (IFN-gamma) and interleukin (IL)-12 p70 levels, but not of IL-10 and tumor necrosis factor-alpha (TNF-alpha), increased significantly (p<0.05-0.006) in phytohemeagglutinin (PHA)+lipopolysaccharide (LPS)-stimulated whole blood. However, no such effect was observed at high concentrations of prolactin (100-300ng/ml). In addition, 15ng/ml of prolactin reversed hydrocortisone suppressive effect on IFN-gamma, IL-12 p70, and IL-10 production in PHA+LPS-stimulated whole blood. On the other hand, in LPS-stimulated whole blood, prolactin enhanced significantly (p=0.027) the production levels of IL-10, but not of IFN-gamma, IL-12 p70, and TNF-alpha, in non-concentration-dependent manner. These results suggest that prolactin modulates cytokine response during antigenic response, and this modulation is stimulus specific.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788307     DOI: 10.1016/s1043-4666(02)00496-9

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  9 in total

1.  Prolactin has a pathogenic role in systemic lupus erythematosus.

Authors:  Luis J Jara; Gabriela Medina; Miguel A Saavedra; Olga Vera-Lastra; Honorio Torres-Aguilar; Carmen Navarro; Monica Vazquez Del Mercado; Luis R Espinoza
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

2.  The HLA-Cw*06 allele and -1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population.

Authors:  Anna Cibulova; Marta Zajacova; Marketa Fojtikova; Jiri Stolfa; Liliana Sedova; Pavlina Cejkova; Jan Lippert; Petr Arenberger; Marie Cerna
Journal:  Rheumatol Int       Date:  2012-07-22       Impact factor: 2.631

3.  HLA-Cw*06 class I region rather than MICA is associated with psoriatic arthritis in Czech population.

Authors:  Markéta Fojtíková; Jirí Stolfa; Peter Novota; Pavlína Cejková; Ctibor Dostál; Marie Cerná
Journal:  Rheumatol Int       Date:  2009-01-28       Impact factor: 2.631

4.  Multiple cAMP-induced signaling cascades regulate prolactin expression in T cells.

Authors:  S Gerlo; P Verdood; E L Hooghe-Peters; R Kooijman
Journal:  Cell Mol Life Sci       Date:  2006-01       Impact factor: 9.261

Review 5.  Women and primary biliary cirrhosis.

Authors:  Ying Sun; Krista Haapanen; Baosen Li; Weici Zhang; Judy Van de Water; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

6.  IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors.

Authors:  Heba A Alshaker; Khalid Z Matalka
Journal:  Cancer Cell Int       Date:  2011-09-23       Impact factor: 5.722

Review 7.  The role of hormones on Toxoplasma gondii infection: a systematic review.

Authors:  María de la Luz Galván-Ramírez; Adrián Fernando Gutiérrez-Maldonado; Fabiola Verduzco-Grijalva; Judith Marcela Dueñas Jiménez
Journal:  Front Microbiol       Date:  2014-10-09       Impact factor: 5.640

Review 8.  The prolactin receptor: Diverse and emerging roles in pathophysiology.

Authors:  Caroline M Gorvin
Journal:  J Clin Transl Endocrinol       Date:  2015-05-16

9.  Repurposing prolactin as a promising immunomodulator for the treatment of COVID-19: Are common Antiemetics the wonder drug to fight coronavirus?

Authors:  Amarnath Sen
Journal:  Med Hypotheses       Date:  2020-08-24       Impact factor: 1.538

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.